Sources · 10
Where Does It Come From?
Principal source Coffee Coffea arabica Herb monograph → 
Source Cacao Theobroma cacao Herb monograph → 
Source Chá de Bugre Cordia salicifolia Herb monograph → 
Source Guarana Paullinia cupana Herb monograph → 
Source Guayusa Ilex guayusa Herb monograph → 
Source Tea Camellia sinensis Herb monograph → 
Source Yerba Maté Ilex paraguariensis Herb monograph → Concentration
Content by Source
Reported concentrations across the plants that contain caffeine — the bar marks the typical level, the line shows the reported range.
Literature figures for varying plant parts and preparations. Read them as a comparative guide, not exact assays.
Caffeine at a Glance
Caffeine is a purine alkaloid found in coffee, tea, cacao, guarana and yerba maté — the most widely used psychoactive substance in the world.
It works by blocking adenosine, the molecule that signals the brain has been awake long enough. Rather than adding energy, it removes the brake. It is also one of the best-studied compounds on this site, with endurance performance and alertness through sleep loss among its strongest results.
What It’s Used For
- Endurance exercise performance — lowers perceived exertion, so the same pace feels easier and holds longer.
- Alertness during sleep loss / shift work — keeps you functional through sleep debt.
- Attention & reaction time — sharpens vigilance and reaction speed.
- Muscle strength & power — improves force output.
- Analgesic adjuvant (headache/pain) — boosts ordinary painkillers, which is why it is in combination headache products.
- Fat oxidation & metabolic rate — raises both.
- Parkinson’s disease risk reduction — associated with lower risk across large populations.
How It Works
Adenosine accumulates through the day and binds A1 and A2A receptors to signal fatigue. Caffeine resembles it closely enough to occupy those receptors without activating them, so the fatigue signal is blocked and the dopamine systems adenosine restrains are disinhibited.
Its half-life runs around five hours, so a mid-afternoon cup still has a quarter of itself circulating at bedtime. The receptors adapt within days, which is why regular users need more for the same effect and why a short break resets it.
The full trial record is in Pharmacology & Research below.
Pharmacology & Research
Caffeine (1,3,7-trimethylxanthine) is a purine alkaloid of the methylxanthine class and the most widely consumed psychoactive substance in the world. Unlike most supplements, its core effects are not in dispute — competitive antagonism of adenosine receptors reliably raises alertness, blunts fatigue, and improves physical performance — so the evidence question is less “does it work” than “for what, how much, and at what cost.” The clearest wins are in exercise (endurance and, to a lesser degree, strength/power) and in restoring performance degraded by sleep loss; several widely marketed uses (fat loss, cognitive enhancement in already-rested people) are real but small. Two caveats run through everything below: much of caffeine’s apparent daily “boost” in habitual users is partly reversal of overnight withdrawal rather than a net gain, and individual response varies with genetics (CYP1A2 metabolism), habituation, and dose.
Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.
Caffeine is one of the few supplements with A-grade sports-nutrition evidence. An umbrella review of 21 meta-analyses concluded caffeine reliably improves aerobic endurance, muscular endurance, and movement velocity 2Reference 2Meta-analysisWake up and smell the coffee: caffeine supplementation and exercise performance — an umbrella review of 21 published meta-analysesView study →.
Pooled analyses put the endurance gain at roughly 2–4% in time-trial and time-to-exhaustion protocols, typically at doses of 3–6 mg/kg taken ~60 minutes before exercise 1,
The effect is genuine (not deficiency-related — everyone starts “replete”) and shows up as reduced perceived exertion as much as raised power output. Caffeinated chewing gum and lower doses (~3 mg/kg) capture most of the benefit with fewer side effects.
Gap: effect size is modest and varies with habitual intake and CYP1A2 genotype; most trials are in trained men, so generalization to women and untrained people is weaker.
This is where caffeine is most clearly a net enhancer rather than withdrawal-reversal. A systematic review and meta-analysis found caffeine restores cognitive, physical, and driving performance degraded by sleep loss 7Reference 7Meta-analysisEffects of acute caffeine consumption following sleep loss on cognitive, physical, occupational and driving performance: A systematic review and meta-analysisView study →.
A Cochrane review concluded caffeine reduces errors and may prevent injuries in shift workers, performing at least as well as napping and comparably to modafinil for maintaining vigilance 8Reference 8Systematic reviewCaffeine for the prevention of injuries and errors in shift workers — [Cochrane review]View study →.
Classic dosing studies show a single 200–300 mg dose reverses much of the alertness and mood decline from a night of sleep deprivation 18Reference 18RCTCaffeine reversal of sleep deprivation effects on alertness and mood — [RCT]View study →.
Gap: benefit is against a sleep-deprived baseline — it does not raise performance above a well-rested state, and repeated use to mask chronic sleep debt carries its own risks.
A 2025 meta-analysis of acute caffeine dosing found a small but statistically robust improvement in attention 10Reference 10Meta-analysisA systematic review and meta-analysis of the acute effect of caffeine on attentionView study →, and in athletes a meta-analysis reported faster reaction time and better accuracy 11Reference 11Meta-analysisCaffeine and Cognitive Functions in Sports: A Systematic Review and Meta-AnalysisView study →.
Effects are most reliable at ~40–300 mg and are clearest in vigilance/sustained-attention tasks rather than complex reasoning. Nehlig’s review frames caffeine as an enhancer of alertness and simple performance rather than a true “smart drug” that improves learning or higher cognition 9Reference 9ReviewIs caffeine a cognitive enhancer? — [review]View study →.
The commonly used L-theanine + caffeine pairing has its own trial support at low caffeine doses: 97 mg L-theanine with 40 mg caffeine improved accuracy on a task-switching test and raised self-reported alertness against placebo in 44 young adults, though visual search, choice reaction time and mental rotation were unaffected 17Reference 17RCTThe combination of L-theanine and caffeine improves cognitive performance and increases subjective alertness — [RCT]View study →.
Gap: hard to separate genuine enhancement from reversal of caffeine withdrawal in habitual users; complex/executive cognition shows little benefit.
Meta-analyses show small but consistent improvements. A systematic review found caffeine increased maximal muscle strength (overall SMD ~0.20) and muscular power 4Reference 4Meta-analysisEffects of caffeine intake on muscle strength and power: a systematic review and meta-analysisView study →; a separate meta-analysis confirmed a modest effect on isokinetic strength 5Reference 5Meta-analysisThe effects of caffeine ingestion on isokinetic muscular strength: A meta-analysisView study →, and a combat-sports meta-analysis found acute performance benefits 6Reference 6Meta-analysisAcute Effects of Caffeine Supplementation on Physical Performance in Combat Sports: A Systematic Review and Meta-AnalysisView study →. Doses of 3–6 mg/kg pre-exercise are typical.
Gap: effect sizes are smaller and less consistent than for endurance; upper-body strength shows clearer gains than lower-body, and trial quality varies.
Caffeine is not a standalone painkiller but boosts other analgesics. A Cochrane review of over 10,000 patients found adding ≥100 mg caffeine to paracetamol or ibuprofen produced a small increase in the number of people getting good pain relief (roughly one extra responder per 14–15 treated) 12,
Gap: the incremental benefit is small; caffeine also causes medication-overuse and rebound headaches with frequent use, complicating the risk-benefit picture.
Observational data are strikingly consistent: a dose-response meta-analysis found higher coffee/tea/caffeine intake associated with lower Parkinson’s risk 19Reference 19Meta-analysisDose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s diseaseView study →, and a later meta-analysis reported both reduced risk and possible slowing of progression 20Reference 20Meta-analysisThe Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-AnalysisView study →. Mechanistically plausible via adenosine A2A receptor antagonism.
Gap: entirely observational — no randomized trial has shown caffeine prevents Parkinson’s, and reverse causation (early Parkinson’s reducing caffeine appetite) cannot be excluded. This is an association, not a demonstrated protective effect.
Caffeine acutely raises fat oxidation and energy expenditure. A meta-analysis confirmed caffeine increases fat metabolism 14Reference 14Meta-analysisDoes Caffeine Increase Fat Metabolism? A Systematic Review and Meta-AnalysisView study →, another found higher fat-oxidation rates during exercise 15Reference 15Meta-analysisEffect of Acute Caffeine Intake on Fat Oxidation Rate during Fed-State Exercise: A Systematic Review and Meta-AnalysisView study →, and controlled feeding studies show measurable rises in 24-h energy expenditure 16Reference 16RCTBioactive food stimulants of sympathetic activity: effect on 24-h energy expenditure and fat oxidation — [RCT]View study →.
But translating this to meaningful fat loss is where the claim thins out: increases are small, partly offset by compensatory appetite and tolerance, and long-term weight outcomes are marginal.
Gap: acute metabolic effects do not reliably produce clinically meaningful weight loss; tolerance blunts the thermogenic response, and most “fat burner” marketing overstates the evidence.
Mechanisms
| Target / pathway | Effect | Relevant to |
|---|---|---|
| Adenosine A1 / A2A receptors | Competitive antagonism → blocks fatigue signaling, disinhibits dopamine | AlertnessenduranceParkinson’smood |
| Central nervous system | Net stimulation; lowers perceived exertion | Exercise performancevigilance |
| Phosphodiesterase | Inhibition (only at high, supra-physiological doses) → ↑ cyclic AMP | Minor contributor at normal doses |
| Ryanodine receptors / calcium handling | ↑ intracellular Ca²⁺ release in muscle (high doses) | Muscle contractility |
| Sympathetic nervous system | ↑ catecholamines → lipolysis, thermogenesis | Fat oxidationmetabolic rate |
At the doses people actually consume, adenosine-receptor antagonism is the dominant mechanism; the phosphodiesterase and calcium effects textbooks cite require concentrations well above normal intake 27Reference 27ReviewAdenosine, adenosine receptors and the actions of caffeine — [review]View study →.
Pharmacokinetics
Caffeine is rapidly and almost completely absorbed, reaching peak blood levels 30–120 minutes after ingestion. It is highly lipophilic, crosses the blood-brain and placental barriers freely, and distributes throughout body water. Metabolism is overwhelmingly hepatic via CYP1A2 (~90–95% of clearance), which is why the enzyme’s wide genetic and environmental variability drives individual response 31Reference 31AnimalRole of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2View study →. The half-life averages ~5 hours (range 3–7 h) in healthy adults but is highly variable: it roughly doubles in pregnancy (up to ~10–15 h in late pregnancy) and with oral contraceptives, is prolonged by CYP1A2 inhibitors (fluvoxamine, ciprofloxacin), and is shortened by smoking, which induces CYP1A2. This variability — not dose alone — explains why the same coffee leaves one person wired at bedtime and another unaffected. Because of the ~5-hour half-life, an afternoon dose still leaves roughly a quarter of the caffeine circulating near bedtime.
Clinical trials
Caffeine is off-patent and ubiquitous, so trial activity is driven by sports-science and academic groups rather than industry; there is an unusually deep evidence base for a substance no company can monopolize. Hundreds of randomized crossover trials exist for exercise and cognition, dozens of meta-analyses and several Cochrane reviews synthesize them, and large observational cohorts cover long-term health outcomes.
| Completed | Planned | Terminated | Preclinical |
|---|---|---|---|
| Hundreds(RCTs + dozens of meta-analyses) | Ongoing(sports/cognition) | Few | Extensive |
Last checked: July 2026.
Dietary Sources
Caffeine occurs naturally in the seeds, leaves, and fruit of more than 60 plant species, where it acts as a natural pesticide. Nearly all human intake comes from a handful of beverages and foods rather than supplements. Content varies widely with preparation, brew strength, and serving size, so the figures below are typical ranges, not fixed values.
| Source | Typical serving | Caffeine (approx.) |
|---|---|---|
| Brewed coffee | 240 ml (8 oz) | 80–120 mg |
| Espresso | 30 ml (1 shot) | 60–75 mg |
| Instant coffee | 240 ml | 60–80 mg |
| Black tea | 240 ml | 40–50 mg |
| Green tea | 240 ml | 25–40 mg |
| Yerba maté | 240 ml | 40–80 mg |
| Cola soft drink | 355 ml (12 oz) | 30–40 mg |
| Energy drink | 250 ml | 75–110 mg |
| Dark chocolate | 30 g (1 oz) | 20–30 mg |
| Decaf coffee | 240 ml | 2–5 mg |
Because caffeine is water-soluble and extracted during brewing, longer steeping and hotter water pull more of it out. Decaffeination removes most but not all — “decaf” is low-caffeine, not caffeine-free. There is no dietary requirement for caffeine; it is a non-essential plant xanthine, so “sources” describe habitual exposure rather than nutritional adequacy. (Beverage figures per USDA and FDA reference data; safety framing per NIH and EFSA.)
Dosage
Caffeine is not an essential nutrient, so there is no RDA, AI, or IOM Tolerable Upper Intake Level. Regulatory bodies instead define a customary “safe” ceiling: the US FDA and EFSA both identify ~400 mg/day as not associated with adverse effects in most healthy non-pregnant adults, with single doses up to ~200 mg considered safe 28,
These are doses studied in research, not a personal recommendation:
- General alertness / mood: 50–200 mg per dose; benefits plateau and side effects rise above ~300 mg acutely.
- Ergogenic (exercise): 3–6 mg/kg body weight (~200–400 mg for a 70 kg adult) taken ~60 minutes before exercise; lower doses (~3 mg/kg) capture most of the benefit with fewer side effects 1,
2Reference 1Meta-analysisThe Effect of Acute Caffeine Ingestion on Endurance Performance: A Systematic Review and Meta-Analysis — [meta-analysis]View study →Reference 2Meta-analysisWake up and smell the coffee: caffeine supplementation and exercise performance — an umbrella review of 21 published meta-analysesView study → . - Analgesic adjuvant: ≥100 mg added to a standard painkiller dose 12Reference 12Systematic reviewCaffeine as an analgesic adjuvant for acute pain in adults — [Cochrane review]View study →.
- Pregnancy: major bodies advise limiting to ≤200 mg/day given the doubled half-life and dose-related birth-outcome associations 24Reference 24Meta-analysisCaffeine intake during pregnancy and adverse birth outcomes: a systematic review and dose-response meta-analysisView study →.
Because caffeine is sold as a single molecule (anhydrous), compound weight equals active weight — a “200 mg caffeine” tablet delivers 200 mg of caffeine, with none of the elemental-vs-salt discrepancy that complicates mineral dosing. The practical variables are timing (afternoon doses linger near bedtime because of the ~5-hour half-life) and habituation (tolerance to many effects builds within days). Anhydrous powder is extremely concentrated — a level teaspoon is roughly a toxic dose — and should never be measured by eye. The nootropic dosage guide works through what the ~5-hour half-life means for a second dose and an afternoon cut-off.
Safety
At customary intakes (≤400 mg/day) caffeine is well tolerated by most healthy adults, but it is a genuine stimulant drug with a clear dose-toxicity curve — and the gap between the beverage experience and concentrated powder is where the real danger sits.
- Well tolerated at ≤400 mg/day. Moderate intake is not associated with atrial fibrillation, and tracks with slightly lower all-cause mortality.
- Concentrated powders have killed people. Acutely toxic effects begin around 1 g and ~10 g can be lethal. Never eyeball bulk anhydrous caffeine.
- Cardiac caution. Small acute rise in blood pressure; be careful with uncontrolled hypertension or a known arrhythmia.
- Dependence and withdrawal are real. Abrupt cessation causes headache, fatigue and low mood peaking at 1–2 days.
- Sleep is the dose-limiting effect. Intake even 6 hours before bed measurably degrades sleep quality.
- CYP1A2 interactions. Fluvoxamine, ciprofloxacin and oral contraceptives slow clearance; tobacco smoke speeds it.
Full Safety & Interactions Detail
At customary intakes (≤400 mg/day) caffeine is well tolerated by most healthy adults, but it is a genuine stimulant drug with a clear dose-toxicity curve. Common, dose-related adverse effects are jitteriness, anxiety, palpitations, gastrointestinal upset, and — most reliably — disrupted sleep. Sleep disruption is the dose-limiting effect for most people: caffeine taken even 6 hours before bed measurably reduces sleep quality. A randomized trial found a single 150 mg dose acutely increased subjective and physiological anxiety, with a larger effect in people with panic disorder 25Reference 25RCTAcute effects of 150 mg caffeine on subjective, physiological, and behavioral components of anxiety in panic disorder and healthy controls — [RCT]View study →.
Blood pressure and heart rhythm: caffeine causes a small acute rise in blood pressure that partly attenuates with habitual use; meta-analyses of chronic intake show only a minor net effect 21,
Dependence and withdrawal: regular use produces physical dependence. Abrupt cessation causes a recognized withdrawal syndrome — headache, fatigue, low mood, difficulty concentrating — peaking at 1–2 days 26Reference 26Clinical trialCaffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration — [clinical trial]View study →. Much of the “boost” habitual users feel is partly reversal of this overnight withdrawal rather than net enhancement.
Overdose: although toxicity is low at dietary doses, concentrated anhydrous caffeine powders and high-dose pills have caused fatalities from arrhythmia and seizures. Acutely toxic effects begin around 1 g and doses near ~10 g can be lethal; the margin is far smaller than the beverage experience suggests.
Interactions (drug class + timing):
- CYP1A2 inhibitors (fluvoxamine and some other SSRIs, ciprofloxacin and other fluoroquinolones, cimetidine) markedly slow caffeine clearance and amplify its effects.
- CYP1A2 inducers (tobacco smoke) speed clearance — smokers often need more; quitting can raise caffeine levels.
- Stimulants / sympathomimetics (ephedrine, pseudoephedrine, some ADHD medications) add cardiovascular stimulation.
- Theophylline (a related methylxanthine) — additive toxicity.
- Adenosine used for cardiac stress testing — caffeine antagonizes it; hold caffeine ~24 h before the test.
- Oral contraceptives roughly double caffeine’s half-life.
Verdict: limit, do not eliminate. Caffeine crosses the placenta freely and its half-life roughly doubles in pregnancy, so the fetus is exposed for longer. A dose-response meta-analysis found maternal caffeine intake associated with increased risk of low birth weight, small-for-gestational-age, and pregnancy loss, with risk rising across the intake range 24Reference 24Meta-analysisCaffeine intake during pregnancy and adverse birth outcomes: a systematic review and dose-response meta-analysisView study →. Major bodies (ACOG, EFSA, WHO) advise ≤200 mg/day during pregnancy. During lactation, caffeine passes into breast milk in small amounts; moderate intake (≤200–300 mg/day) is generally considered compatible, though very high intake may make some infants irritable or wakeful. This is general information, not personalized medical advice — pregnant or breastfeeding individuals should confirm their own limit with their clinician.
References
- Southward K et al. (2018). The Effect of Acute Caffeine Ingestion on Endurance Performance: A Systematic Review and Meta-Analysis — [meta-analysis]. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/29876876/
- Grgic J et al. (2020). Wake up and smell the coffee: caffeine supplementation and exercise performance — an umbrella review of 21 published meta-analyses. British Journal of Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/30926628/
- Wang Z et al. (2022). Effects of Caffeine Intake on Endurance Running Performance and Time to Exhaustion: A Systematic Review and Meta-Analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/36615805/
- Grgic J et al. (2018). Effects of caffeine intake on muscle strength and power: a systematic review and meta-analysis. Journal of the International Society of Sports Nutrition. https://pubmed.ncbi.nlm.nih.gov/29527137/
- Grgic J et al. (2019). The effects of caffeine ingestion on isokinetic muscular strength: A meta-analysis. Journal of Science and Medicine in Sport. https://pubmed.ncbi.nlm.nih.gov/30217692/
- Delleli S et al. (2022). Acute Effects of Caffeine Supplementation on Physical Performance in Combat Sports: A Systematic Review and Meta-Analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/35889953/
- Irwin C et al. (2020). Effects of acute caffeine consumption following sleep loss on cognitive, physical, occupational and driving performance: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. https://pubmed.ncbi.nlm.nih.gov/31837359/
- Ker K et al. (2010). Caffeine for the prevention of injuries and errors in shift workers — [Cochrane review]. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/20464765/
- Nehlig A (2010). Is caffeine a cognitive enhancer? — [review]. Journal of Alzheimer’s Disease. https://pubmed.ncbi.nlm.nih.gov/20182035/
- Kløve K et al. (2025). A systematic review and meta-analysis of the acute effect of caffeine on attention. Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/40335666/
- Lorenzo Calvo J et al. (2021). Caffeine and Cognitive Functions in Sports: A Systematic Review and Meta-Analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/33800853/
- Derry CJ et al. (2014). Caffeine as an analgesic adjuvant for acute pain in adults — [Cochrane review]. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/25502052/
- Derry CJ et al. (2012). Caffeine as an analgesic adjuvant for acute pain in adults — [Cochrane review]. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/22419343/
- Conger SA et al. (2023). Does Caffeine Increase Fat Metabolism? A Systematic Review and Meta-Analysis. International Journal of Sport Nutrition and Exercise Metabolism. https://pubmed.ncbi.nlm.nih.gov/36495873/
- Fernández-Sánchez J et al. (2024). Effect of Acute Caffeine Intake on Fat Oxidation Rate during Fed-State Exercise: A Systematic Review and Meta-Analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/38257100/
- Belza A et al. (2005). Bioactive food stimulants of sympathetic activity: effect on 24-h energy expenditure and fat oxidation — [RCT]. European Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/15870822/
- Giesbrecht T et al. (2010). The combination of L-theanine and caffeine improves cognitive performance and increases subjective alertness — [RCT]. Nutritional Neuroscience. https://pubmed.ncbi.nlm.nih.gov/21040626/
- Penetar D et al. (1993). Caffeine reversal of sleep deprivation effects on alertness and mood — [RCT]. Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/7871042/
- Qi H et al. (2014). Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatrics & Gerontology International. https://pubmed.ncbi.nlm.nih.gov/23879665/
- Hong CT et al. (2020). The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/32580456/
- Noordzij M et al. (2005). Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension. https://pubmed.ncbi.nlm.nih.gov/15834273/
- Abbas-Hashemi SA et al. (2023). The effects of caffeine supplementation on blood pressure in adults: A systematic review and dose-response meta-analysis. Clinical Nutrition ESPEN. https://pubmed.ncbi.nlm.nih.gov/38057002/
- Cheng M et al. (2014). Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies. Canadian Journal of Cardiology. https://pubmed.ncbi.nlm.nih.gov/24680173/
- Greenwood DC et al. (2014). Caffeine intake during pregnancy and adverse birth outcomes: a systematic review and dose-response meta-analysis. European Journal of Epidemiology. https://pubmed.ncbi.nlm.nih.gov/25179792/
- Hoppe JM et al. (2025). Acute effects of 150 mg caffeine on subjective, physiological, and behavioral components of anxiety in panic disorder and healthy controls — [RCT]. Journal of Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/40577029/
- Sigmon SC et al. (2009). Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration — [clinical trial]. Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/19241060/
- Fredholm BB (1995). Adenosine, adenosine receptors and the actions of caffeine — [review]. Pharmacology & Toxicology. https://pubmed.ncbi.nlm.nih.gov/7746802/
- Grosso G et al. (2017). Coffee, Caffeine, and Health Outcomes: An Umbrella Review. Annual Review of Nutrition. https://pubmed.ncbi.nlm.nih.gov/28826374/
- Wikoff D et al. (2017). Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food and Chemical Toxicology. https://pubmed.ncbi.nlm.nih.gov/28438661/
- Li Q et al. (2019). Caffeinated and decaffeinated coffee consumption and risk of all-cause mortality: a dose-response meta-analysis of cohort studies. Journal of Human Nutrition and Dietetics. https://pubmed.ncbi.nlm.nih.gov/30786114/
- Buters JT et al. (1996). Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics. https://pubmed.ncbi.nlm.nih.gov/8873215/
For half-lives, timing and stacking across the nootropics on this site, see the Nootropic Dosage Guide.
